Last reviewed · How we verify
Specific anti-SARS-CoV-2 antibodies
At a glance
| Generic name | Specific anti-SARS-CoV-2 antibodies |
|---|---|
| Sponsor | Egyptian Center for Research and Regenerative Medicine |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection (NA)
- Covid-19 Vaccine Response in Elderly Subjects
- Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19 (NA)
- SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia
- Spike-specific Cellular Immune Response After COVID-19 Vaccination
- Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups. (NA)
- A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study
- Comparative Analysis of Anti-COVID-19 (Severe Acute Respiratory Syndrome) Humoral and Memory T Cell Responses in Children With Various Degrees of Immunosuppression:
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: